Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 15/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | NFKBIA | P25963 | 3/20 | 0.76 |
| ▸ | RELA | Q04206 | 2/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.76 |
| ▸ | MMP2 | P08253 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.70 |
| ▸ | G6PD | P11413 | 1/20 | 0.70 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.70 |
| ▸ | METAP2 | P50579 | 1/20 | 0.70 |
| ▸ | METAP1 | P53582 | 1/20 | 0.70 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | MDM4 | O15151 | 1/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.69 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30854809 | 1.00 | SLC40A1 (0.76) | SLC40A1TDP1MEN1KMT2ANFKBIA | |
| SCHEMBL27214283 | 0.89 | SLC40A1 (0.80) | SLC40A1TDP1MEN1KMT2ANFKBIA | |
| SCHEMBL30925525 | 0.89 | SLC40A1 (0.80) | SLC40A1TDP1MEN1KMT2ANFKBIA | |
| SCHEMBL6981201 | 0.88 | SLC40A1 (0.73) | SLC40A1TDP1MEN1KMT2ANFKBIA | |
| SCHEMBL30925552 | 0.88 | SLC40A1 (0.78) | SLC40A1TDP1MEN1KMT2ANFKBIA | |
| SCHEMBL27214248 | 0.88 | SLC40A1 (0.78) | SLC40A1TDP1MEN1KMT2ANFKBIA | |
| SCHEMBL29255667 | 0.87 | SLC40A1 (0.72) | SLC40A1TDP1MEN1KMT2ANFKBIA | |
| SCHEMBL29255668 | 0.87 | SLC40A1 (0.68) | SLC40A1TDP1MEN1KMT2ANFKBIA | |
| SCHEMBL30854820 | 0.87 | SLC40A1 (0.68) | SLC40A1TDP1MEN1KMT2ANFKBIA | |
| SCHEMBL30854816 | 0.87 | SLC40A1 (0.72) | SLC40A1TDP1MEN1KMT2ANFKBIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865886-B | N- (quinoline-8-yl) quinoline-8-sulfonamide compound and application thereof | 中国药科大学 | 2024-05-10 | — | — | CN | claimed |
| CN-117865886-A | N- (quinoline-8-yl) quinoline-8-sulfonamide compound and application thereof | 中国药科大学 | 2024-04-12 | — | — | CN | claimed |
| US-20090227626-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | PALUMED S.A. (FR) | 2009-09-10 | — | — | US | claimed |
| CN-117865886-B | N- (quinoline-8-yl) quinoline-8-sulfonamide compound and application thereof | 中国药科大学 | 2024-05-10 | — | — | CN | disclosed |
| CN-117865886-B | N- (quinoline-8-yl) quinoline-8-sulfonamide compound and application thereof | 中国药科大学 | 2024-05-10 | — | — | CN | disclosed |
| CN-117865886-B | N- (quinoline-8-yl) quinoline-8-sulfonamide compound and application thereof | 中国药科大学 | 2024-05-10 | — | — | CN | disclosed |
| CN-117865886-A | N- (quinoline-8-yl) quinoline-8-sulfonamide compound and application thereof | 中国药科大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-117865886-A | N- (quinoline-8-yl) quinoline-8-sulfonamide compound and application thereof | 中国药科大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-117865886-A | N- (quinoline-8-yl) quinoline-8-sulfonamide compound and application thereof | 中国药科大学 | 2024-04-12 | — | — | CN | disclosed |
| US-8324196-B2 | Polyquinoline derivatives and the therapeutic use thereof | PALUMED S.A. (FR) | 2012-12-04 | — | — | US | disclosed |
| US-20120277265-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2012-11-01 | — | — | US | disclosed |
| US-8247396-B2 | Polyquinoline derivatives and therapeutic use thereof | PALUMED S.A. (FR) | 2012-08-21 | — | — | US | disclosed |
| EP-2289891-A2 | Novel polyquinoline derivates and the therapeutic use thereof | Palumed S.A. (FR) | 2011-03-02 | — | — | EP | disclosed |
| EP-2289891-A2 | Novel polyquinoline derivates and the therapeutic use thereof | Palumed S.A. (FR) | 2011-03-02 | — | — | EP | disclosed |
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090227626-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | PALUMED S.A. (FR) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277265-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | HTT, APP, PSEN1 | SLC40A1 124/4885TDP1 616/4885MEN1 1196/4885 |
| US-20090227626-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | HTT, UBQLN2, UBQLN1 | SLC40A1 2081/4885TDP1 860/4885MEN1 1574/4885 |
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | HELZ, MMEL1, GAA | SLC40A1 408/4885TDP1 1854/4885MEN1 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.